10,829 Shares in Progyny, Inc. (NASDAQ:PGNY) Acquired by Ballentine Partners LLC

Ballentine Partners LLC bought a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 4th quarter, Holdings Channel.com reports. The fund bought 10,829 shares of the company’s stock, valued at approximately $187,000.

Several other hedge funds also recently bought and sold shares of PGNY. Leibman Financial Services Inc. increased its position in shares of Progyny by 100.7% in the 4th quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock valued at $1,096,000 after buying an additional 31,872 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Progyny by 5.8% in the fourth quarter. Nordea Investment Management AB now owns 185,042 shares of the company’s stock worth $3,175,000 after acquiring an additional 10,203 shares in the last quarter. Central Pacific Bank Trust Division raised its position in shares of Progyny by 89.8% during the fourth quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company’s stock worth $229,000 after purchasing an additional 6,270 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after purchasing an additional 1,246 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Progyny by 17.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,248 shares of the company’s stock valued at $759,000 after purchasing an additional 7,003 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Trading Up 0.3 %

NASDAQ PGNY opened at $22.09 on Friday. The firm’s fifty day moving average price is $16.73 and its two-hundred day moving average price is $19.34. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $42.08. The firm has a market capitalization of $1.88 billion, a P/E ratio of 38.09, a price-to-earnings-growth ratio of 2.11 and a beta of 1.31.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). The firm had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the business posted $0.16 earnings per share. On average, research analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Chairman David J. Schlanger purchased 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the purchase, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Peter Anevski acquired 209,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by insiders.

Analyst Ratings Changes

PGNY has been the topic of a number of research reports. Canaccord Genuity Group cut their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $17.00 target price (down from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Truist Financial reissued a “hold” rating and issued a $19.00 price target (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Bank of America reduced their price objective on Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Barclays dropped their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Progyny currently has an average rating of “Hold” and a consensus target price of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.